Downloads
Article: What's Next For Pfizer R&D
By Cliff Mintz Ph.D.
The enormous size of Pfizer, coupled with a large and growing portfolio of small molecule and biologic drugs, demands careful operational oversight and insightful strategic leadership. One Pfizer executive who has been doing that for the past 15 years is Martin Mackay, Ph.D., president of Pfizer PharmaTherapeutics Research & Development. Almost immediately after Pfizer announced it would acquire Wyeth in late 2009, Dr. Mackay was appointed to his current position to oversee and manage the integration of the two drug makers and manage the combined drug company's greatly expanded product portfolio. Despite a hectic travel schedule (he is currently visiting all of Pfizer's global R&D sites), Dr. Mackay found time to chat with me about the Wyeth acquisition, Pfizer's product pipeline, and the future direction of the combined company.
Used with permission from Life Science Leader magazine.
The content you requested is only available to registered users of Pharmaceutical Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
